Segmental Copy Number Variant Detection Using an Amplicon-based NGS Panel for Integrated Glioma Classification.
Standard DNA sequencing panels can now detect the genetic changes needed to classify gliomas precisely, improving access to personalized brain cancer care.
This J Mol Diagn validation study demonstrates that amplicon-based NGS panels can accurately detect segmental CNVs (1p/19q co-deletion, CDKN2A/B homozygous deletion) needed for WHO 2021 integrated glioma classification. The approach enables comprehensive molecular glioma typing using standard sequencing infrastructure, improving accessibility of precision neuro-oncology diagnostics.
What the study was
- Study design
- Diagnostic validation study
- Population
- Glioma patients requiring WHO 2021 integrated molecular classification
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The Journal of molecular diagnostics
Why it surfaced
J Mol Diagn; enabling WHO 2021 glioma classification via amplicon-NGS is directly implementable in molecular pathology labs; Sadikovic co-author (genomic lab medicine leader).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.